MX2018008849A - Diagnostico diferencial de sindrome de cushing ectopico. - Google Patents

Diagnostico diferencial de sindrome de cushing ectopico.

Info

Publication number
MX2018008849A
MX2018008849A MX2018008849A MX2018008849A MX2018008849A MX 2018008849 A MX2018008849 A MX 2018008849A MX 2018008849 A MX2018008849 A MX 2018008849A MX 2018008849 A MX2018008849 A MX 2018008849A MX 2018008849 A MX2018008849 A MX 2018008849A
Authority
MX
Mexico
Prior art keywords
cortisol
acth
syndrome
cushing
levels
Prior art date
Application number
MX2018008849A
Other languages
English (en)
Inventor
G Moraitis Andreas
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2018008849A publication Critical patent/MX2018008849A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A61B5/4227—Evaluating particular parts, e.g. particular organs endocrine glands, i.e. thyroid, adrenals, hypothalamic, pituitary
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Abstract

En la presente se proporcionan métodos y sistemas mejorados para el diagnóstico diferencial del síndrome de Cushing dependiente de ACTH. Los métodos de tratamiento pueden usar antagonistas de receptores de glucocorticoides, que afectan diferencialmente la relación de niveles de cortisol a ACTH en pacientes con enfermedad de Cushing versus pacientes con síndrome de Cushing ectópico. Los métodos para diagnosticar diferencialmente el síndrome de Cushing dependiente de ACTH pueden incluir obtener los niveles basales de cortisol y ACTH, tratar al paciente con un antagonista del receptor de glucocorticoides (GRA) de acuerdo con un protocolo que típicamente elevaría sustancialmente los niveles de cortisol, obteniendo los niveles de cortisol y ACTH del paciente, que determinan una relación diferencial entre los niveles basales de cortisol y los niveles de ACTH y los niveles de cortisol y ACTH posteriores al tratamiento, y proporcionan un diagnóstico positivo basado en la relación diferencial.
MX2018008849A 2016-01-19 2017-01-18 Diagnostico diferencial de sindrome de cushing ectopico. MX2018008849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662280424P 2016-01-19 2016-01-19
PCT/US2017/013974 WO2017127448A1 (en) 2016-01-19 2017-01-18 Differential diagnosis of ectopic cushing's syndrome

Publications (1)

Publication Number Publication Date
MX2018008849A true MX2018008849A (es) 2019-01-31

Family

ID=59362838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008849A MX2018008849A (es) 2016-01-19 2017-01-18 Diagnostico diferencial de sindrome de cushing ectopico.

Country Status (11)

Country Link
US (2) US10151763B2 (es)
EP (1) EP3405101B1 (es)
JP (1) JP6765443B2 (es)
KR (1) KR102197526B1 (es)
AU (1) AU2017210156B2 (es)
CA (1) CA3011728A1 (es)
ES (1) ES2861524T3 (es)
IL (1) IL260687B (es)
MX (1) MX2018008849A (es)
SG (1) SG11201806101SA (es)
WO (1) WO2017127448A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3405101B1 (en) 2016-01-19 2020-12-23 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
US11202787B2 (en) 2018-07-02 2021-12-21 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US10780097B2 (en) 2018-07-02 2020-09-22 Corcept Therapeutics, Inc. Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US20230358768A1 (en) * 2019-12-21 2023-11-09 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
AU580843B2 (en) 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5506354A (en) 1985-09-12 1996-04-09 The Upjohn Company Imidazolylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
ES2015047B3 (es) 1986-07-23 1990-08-01 Akzo Nv Nuevos derivados de 18-fenilestrano.
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
BE1004905A4 (fr) 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DK0683172T3 (da) 1994-05-19 1998-03-30 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnanderivater
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
US5693646A (en) 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
DK0800519T3 (da) 1994-12-22 2004-03-01 Ligand Pharm Inc Steroidreceptormodulatorforbindelser og fremgangsmåder
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
AU2002366217A1 (en) 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
WO2004036377A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Configuring and testing treatment therapy parameters for a medical device system
AU2003291322B2 (en) 2002-11-05 2008-09-25 Corcept Therapeutics, Inc. Methods for treating gastroesophageal reflux disease
DE602005009530D1 (de) 2004-01-09 2008-10-16 Corcept Therapeutics Inc Azadecalinmodulatoren des glucocorticoidrezeptors
AU2005222421B2 (en) 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
PT1778236E (pt) 2004-07-02 2010-10-19 Corcept Therapeutics Inc Moduladores do receptor de glucocorticóide de pirimidina modificada
CN101528707B (zh) 2006-10-23 2012-11-07 默沙东公司 用作糖皮质激素受体配体的2-[1-苯基-5-羟基或甲氧基-4α-甲基-六氢环戊二烯并[f]吲唑-5-基]乙基苯基衍生物
EP2532350A1 (en) 2007-10-17 2012-12-12 Laboratoire HRA Pharma Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
CA2869442C (en) 2012-04-12 2020-09-08 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20140170768A1 (en) * 2012-12-14 2014-06-19 Joel R. L. Ehrenkranz Method for monitoring and assessing pituitary function
JP2015159766A (ja) 2014-02-27 2015-09-07 国立大学法人京都大学 クッシング症候群の検査方法、検査用バイオマーカー及び治療剤
EP3405101B1 (en) 2016-01-19 2020-12-23 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome

Also Published As

Publication number Publication date
US11327083B2 (en) 2022-05-10
KR20180096803A (ko) 2018-08-29
EP3405101B1 (en) 2020-12-23
SG11201806101SA (en) 2018-08-30
US20180011113A1 (en) 2018-01-11
EP3405101A1 (en) 2018-11-28
ES2861524T3 (es) 2021-10-06
US20190041409A1 (en) 2019-02-07
AU2017210156A1 (en) 2018-09-06
JP6765443B2 (ja) 2020-10-07
US10151763B2 (en) 2018-12-11
AU2017210156B2 (en) 2021-10-28
EP3405101A4 (en) 2019-07-24
IL260687B (en) 2022-03-01
WO2017127448A1 (en) 2017-07-27
JP2019503495A (ja) 2019-02-07
CA3011728A1 (en) 2017-07-27
KR102197526B1 (ko) 2020-12-31

Similar Documents

Publication Publication Date Title
IL271230A (en) Compounds interacting with the ras superfamily for the treatment of cancer, inflammation, ras pathologies and fibrotic diseases
MX2018008849A (es) Diagnostico diferencial de sindrome de cushing ectopico.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2018001803A (es) Metodo para disgnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
GB2548942A (en) Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
IL272821A (en) TIM-3 antagonists for the treatment and diagnosis of cancer
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2019012419A (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
EP3554353A4 (en) SYSTEM FOR CHARACTERIZING, DIAGNOSING AND TREATING A HEALTH CONDITION OF A PATIENT AND METHOD FOR USE THEREOF
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
MX2017011937A (es) Antagonistas del receptor de nk-3 para el tratamiento terapeutico o cosmetico de la grasa corporal excesiva.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
WO2015127168A3 (en) Discriminating braf mutations
福山美季 et al. Factors influencing the decision-making of elderly acute leukemia patients in Japan regarding their treatment
JP2014240383A5 (es)
Goto Reversible posterior leukoencephalopathy syndrome in an elderly patient: case report